---
title: Complete Remission with Partial Hematological Recovery as a Palliative Endpoint
  for Treatment of Acute Myeloid Leukemia
date: '2024-05-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38728428/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240511181524&v=2.18.0.post9+e462414
source: Blood
description: Complete remission with partial hematological recovery (CRh) has been
  used as an efficacy endpoint in clinical trials of nonmyelosuppressive drugs for
  acute myeloid leukemia (AML). We conducted a pooled analysis to characterize the
  clinical outcomes for patients with AML who achieved CRh after treatment with ivosidenib,
  olutasidenib, enasidenib, or gilteritinib monotherapy in clinical trials used to
  support marketing applications. The study cohort included 841 adult patients treated
  at ...
disable_comments: true
---
Complete remission with partial hematological recovery (CRh) has been used as an efficacy endpoint in clinical trials of nonmyelosuppressive drugs for acute myeloid leukemia (AML). We conducted a pooled analysis to characterize the clinical outcomes for patients with AML who achieved CRh after treatment with ivosidenib, olutasidenib, enasidenib, or gilteritinib monotherapy in clinical trials used to support marketing applications. The study cohort included 841 adult patients treated at ...